1887

Abstract

Poliovirus (PV) and enterovirus 71 (EV71) cause severe neurological symptoms in their infections of the central nervous system. To identify compounds with anti-PV and anti-EV71 activities that would not allow the emergence of resistant mutants, we performed drug screening by utilizing a pharmacologically active compound library targeting cellular factors with PV and EV71 pseudoviruses that encapsidated luciferase-encoding replicons. We have found that metrifudil (-[2-methylphenyl]methyl)-adenosine) (an A2 adenosine receptor agonist), -benzyladenosine (an A1 adenosine receptor agonist) and NF449 (4,4′,4″,4″′-[carbonylbis[imino-5,1,3-benzenetriyl bis(carbonyl-imino)]] tetrakis (benzene-1,3-disulfonic acid) octasodium salt) (a Gs- inhibitor) have anti-EV71 activity, and that GW5074 (3-(3, 5-dibromo-4-hydroxybenzylidine-5-iodo-1,3-dihydro-indol-2-one)) (a Raf-1 inhibitor) has both anti-PV and anti-EV71 activities. EV71 mutants resistant to metrifudil, -benzyladenosine and NF449 were isolated after passages in the presence of these compounds, but mutants resistant to GW5074 were not isolated for both PV and EV71. The inhibitory effect of GW5074 was not observed in Sendai virus infection and the treatment did not induce the expression of OAS1 and STAT1 mRNA. Small interfering RNA treatment against putative cellular targets of GW5074, including Raf-1, B-Raf, Pim-1, -2, and -3, HIPK2, GAK, MST2 and ATF-3, did not consistently suppress PV replication. Moreover, downregulation of Raf-1 and B-Raf did not affect the sensitivity of RD cells to the inhibitory effect of GW5074. These results suggest that GW5074 has strong and selective inhibitory effect against the replication of PV and EV71 by inhibiting conserved targets in the infection independently of the interferon response.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.2008/002915-0
2008-10-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/10/2518.html?itemId=/content/journal/jgv/10.1099/vir.0.2008/002915-0&mimeType=html&fmt=ahah

References

  1. Abdel-Rahman S. M., Kearns G. L. 1998; Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food. Antimicrob Agents Chemother 42:2706–2709
    [Google Scholar]
  2. Arita M., Nagata N., Sata T., Miyamura T., Shimizu H. 2006; Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J Gen Virol 87:3317–3327 [CrossRef]
    [Google Scholar]
  3. Arita M., Nagata N., Iwata N., Ami Y., Suzaki Y., Mizuta K., Iwasaki T., Sata T., Wakita T., Shimizu H. 2007; An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81:9386–9395 [CrossRef]
    [Google Scholar]
  4. Arita M., Ami Y., Wakita T., Shimizu H. 2008; Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol 82:1787–1797 [CrossRef]
    [Google Scholar]
  5. Bain J., Plater L., Elliott M., Shpiro N., Hastie J., McLauchlan H., Klevernic I., Arthur S., Alessi D., Cohen P. 2007; The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297–315 [CrossRef]
    [Google Scholar]
  6. Bedard K. M., Daijogo S., Semler B. L. 2007; A nucleo-cytoplasmic SR protein functions in viral IRES-mediated translation initiation. EMBO J 26:459–467 [CrossRef]
    [Google Scholar]
  7. Belov G. A., Habbersett C., Franco D., Ehrenfeld E. 2007; Activation of cellular Arf GTPases by poliovirus protein 3CD correlates with virus replication. J Virol 81:9259–9267 [CrossRef]
    [Google Scholar]
  8. Blondel B., Crainic R., Fichot O., Dufraisse G., Candrea A., Diamond D., Girard M., Horaud F. 1986; Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J Virol 57:81–90
    [Google Scholar]
  9. Bodian D. 1949; Histopathologic basis of clinical findings in poliomyelitis. Am J Med 6:563–578 [CrossRef]
    [Google Scholar]
  10. Bubeck D., Filman D. J., Hogle J. M. 2005; Cryo-electron microscopy reconstruction of a poliovirus-receptor-membrane complex. Nat Struct Mol Biol 12:615–618 [CrossRef]
    [Google Scholar]
  11. Chang L. Y., Lin T. Y., Hsu K. H., Huang Y. C., Lin K. L., Hsueh C., Shih S. R., Ning H. C., Hwang M. S. other authors 1999; Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354:1682–1686 [CrossRef]
    [Google Scholar]
  12. Chen H. F., Chang M. H., Chiang B. L., Jeng S. T. 2006; Oral immunization of mice using transgenic tomato fruit expressing protein VP1 from enterovirus 71. Vaccine 24:2944–2951 [CrossRef]
    [Google Scholar]
  13. Chen H. M., Wang L., D'Mello S. R. 2008; Inhibition of ATF-3 expression by B-Raf mediates the neuroprotective action of GW5074. J Neurochem 105:1300–1312 [CrossRef]
    [Google Scholar]
  14. Chiu C. H., Chu C., He C. C., Lin T. Y. 2006; Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8:1671–1678 [CrossRef]
    [Google Scholar]
  15. Chumakov M., Voroshilova M., Shindarov L., Lavrova I., Gracheva L., Koroleva G., Vasilenko S., Brodvarova I., Nikolova M. other authors 1979; Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 60:329–340 [CrossRef]
    [Google Scholar]
  16. Crotty S., Cameron C. E., Andino R. 2001; RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98:6895–6900 [CrossRef]
    [Google Scholar]
  17. Crotty S., Hix L., Sigal L. J., Andino R. 2002; Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J Gen Virol 83:1707–1720
    [Google Scholar]
  18. Crotty S., Saleh M. C., Gitlin L., Beske O., Andino R. 2004; The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J Virol 78:3378–3386 [CrossRef]
    [Google Scholar]
  19. de la Torre J. C., Giachetti C., Semler B. L., Holland J. J. 1992; High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus. Proc Natl Acad Sci U S A 89:2531–2535 [CrossRef]
    [Google Scholar]
  20. Diamond D. C., Jameson B. A., Bonin J., Kohara M., Abe S., Itoh H., Komatsu T., Arita M., Kuge S. other authors 1985; Antigenic variation and resistance to neutralization in poliovirus type 1. Science 229:1090–1093 [CrossRef]
    [Google Scholar]
  21. Elbashir S. M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. 2001; Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498 [CrossRef]
    [Google Scholar]
  22. Esfandiarei M., Luo H., Yanagawa B., Suarez A., Dabiri D., Zhang J., McManus B. M. 2004; Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol 78:4289–4298 [CrossRef]
    [Google Scholar]
  23. Geller R., Vignuzzi M., Andino R., Frydman J. 2007; Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 21:195–205 [CrossRef]
    [Google Scholar]
  24. Gradi A., Svitkin Y. V., Imataka H., Sonenberg N. 1998; Proteolysis of human eukaryotic translation initiation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. Proc Natl Acad Sci U S A 95:11089–11094 [CrossRef]
    [Google Scholar]
  25. Graham F. L., Smiley J., Russell W. C., Nairn R. 1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59–74 [CrossRef]
    [Google Scholar]
  26. Hasan M. K., Kato A., Shioda T., Sakai Y., Yu D., Nagai Y. 1997; Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus. J Gen Virol 78:2813–2820
    [Google Scholar]
  27. Hellen C. U., Witherell G. W., Schmid M., Shin S. H., Pestova T. V., Gil A., Wimmer E. 1993; A cytoplasmic 57-kDa protein that is required for translation of picornavirus RNA by internal ribosomal entry is identical to the nuclear pyrimidine tract-binding protein. Proc Natl Acad Sci U S A 90:7642–7646 [CrossRef]
    [Google Scholar]
  28. Ho M., Chen E. R., Hsu K. H., Twu S. J., Chen K. T., Tsai S. F., Wang J. R., Shih S. R. 1999; An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 341:929–935 [CrossRef]
    [Google Scholar]
  29. Huang C. C., Liu C. C., Chang Y. C., Chen C. Y., Wang S. T., Yeh T. F. 1999; Neurologic complications in children with enterovirus 71 infection. N Engl J Med 341:936–942 [CrossRef]
    [Google Scholar]
  30. Hunt S. L., Hsuan J. J., Totty N., Jackson R. J. 1999; unr, a cellular cytoplasmic RNA-binding protein with five cold-shock domains, is required for internal initiation of translation of human rhinovirus RNA. Genes Dev 13:437–448 [CrossRef]
    [Google Scholar]
  31. Ida-Hosonuma M., Iwasaki T., Taya C., Sato Y., Li J., Nagata N., Yonekawa H., Koike S. 2002; Comparison of neuropathogenicity of poliovirus in two transgenic mouse strains expressing human poliovirus receptor with different distribution patterns. J Gen Virol 83:1095–1105
    [Google Scholar]
  32. Irurzun A., Perez L., Carrasco L. 1992; Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191:166–175 [CrossRef]
    [Google Scholar]
  33. Kärber G. 1931; Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch Pharmacol 162:480–483 [CrossRef]
    [Google Scholar]
  34. Koike S., Taya C., Aoki J., Matsuda Y., Ise I., Takeda H., Matsuzaki T., Amanuma H., Yonekawa H., Nomoto A. 1994; Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene -- influence of the transgene expression on pathogenesis. Arch Virol 139:351–363 [CrossRef]
    [Google Scholar]
  35. Komatsu H., Shimizu Y., Takeuchi Y., Ishiko H., Takada H. 1999; Outbreak of severe neurologic involvement associated with enterovirus 71 infection. Pediatr Neurol 20:17–23 [CrossRef]
    [Google Scholar]
  36. Krausslich H. G., Nicklin M. J., Toyoda H., Etchison D., Wimmer E. 1987; Poliovirus proteinase 2A induces cleavage of eucaryotic initiation factor 4F polypeptide p220. J Virol 61:2711–2718
    [Google Scholar]
  37. Lackey K., Cory M., Davis R., Frye S. V., Harris P. A., Hunter R. N., Jung D. K., McDonald O. B., McNutt R. W. other authors 2000; The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett 10:223–226 [CrossRef]
    [Google Scholar]
  38. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 [CrossRef]
    [Google Scholar]
  39. Liu M. L., Lee Y. P., Wang Y. F., Lei H. Y., Liu C. C., Wang S. M., Su I. J., Wang J. R., Yeh T. M. other authors 2005; Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 86:3263–3269 [CrossRef]
    [Google Scholar]
  40. Liu C. C., Lian W. C., Butler M., Wu S. C. 2007; High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25:19–24 [CrossRef]
    [Google Scholar]
  41. Lum L. C., Wong K. T., Lam S. K., Chua K. B., Goh A. Y., Lim W. L., Ong B. B., Paul G., AbuBakar S., Lambert M. 1998; Fatal enterovirus 71 encephalomyelitis. J Pediatr 133:795–798 [CrossRef]
    [Google Scholar]
  42. Luo H., Yanagawa B., Zhang J., Luo Z., Zhang M., Esfandiarei M., Carthy C., Wilson J. E., Yang D., McManus B. M. 2002; Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J Virol 76:3365–3373 [CrossRef]
    [Google Scholar]
  43. Macejak D. G., Sarnow P. 1992; Association of heat shock protein 70 with enterovirus capsid precursor P1 in infected human cells. J Virol 66:1520–1527
    [Google Scholar]
  44. MacLennan C., Dunn G., Huissoon A. P., Kumararatne D. S., Martin J., O'Leary P., Thompson R. A., Osman H., Wood P. other authors 2004; Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363:1509–1513 [CrossRef]
    [Google Scholar]
  45. Maynell L. A., Kirkegaard K., Klymkowsky M. W. 1992; Inhibition of poliovirus RNA synthesis by brefeldin A. J Virol 66:1985–1994
    [Google Scholar]
  46. McMinn P. C. 2002; An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91–107 [CrossRef]
    [Google Scholar]
  47. Meerovitch K., Svitkin Y. V., Lee H. S., Lejbkowicz F., Kenan D. J., Chan E. K., Agol V. I., Keene J. D., Sonenberg N. 1993; La autoantigen enhances and corrects aberrant translation of poliovirus RNA in reticulocyte lysate. J Virol 67:3798–3807
    [Google Scholar]
  48. Mendelsohn C. L., Wimmer E., Racaniello V. R. 1989; Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855–865 [CrossRef]
    [Google Scholar]
  49. Minor P. D. 1992; The molecular biology of polio vaccines. J Gen Virol 73:3065–3077 [CrossRef]
    [Google Scholar]
  50. Nagata N., Shimizu H., Ami Y., Tano Y., Harashima A., Suzaki Y., Sato Y., Miyamura T., Sata T., Iwasaki T. 2002; Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol 67:207–216 [CrossRef]
    [Google Scholar]
  51. Nijhuis M., van Maarseveen N., Schuurman R., Verkuijlen S., de Vos M., Hendriksen K., van Loon A. M. 2002; Rapid and sensitive routine detection of all members of the genus enterovirus in different clinical specimens by real-time PCR. J Clin Microbiol 40:3666–3670 [CrossRef]
    [Google Scholar]
  52. Nkowane B. M., Wassilak S. G., Orenstein W. A., Bart K. J., Schonberger L. B., Hinman A. R., Kew O. M. 1987; Vaccine-associated paralytic poliomyelitis. United States 1973 through 1984 JAMA 257:1335–1340 [CrossRef]
    [Google Scholar]
  53. Pfister T., Wimmer E. 1999; Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J Biol Chem 274:6992–7001 [CrossRef]
    [Google Scholar]
  54. Pincus S. E., Diamond D. C., Emini E. A., Wimmer E. 1986; Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C. J Virol 57:638–646
    [Google Scholar]
  55. Pincus S. E., Rohl H., Wimmer E. 1987; Guanidine-dependent mutants of poliovirus: identification of three classes with different growth requirements. Virology 157:83–88 [CrossRef]
    [Google Scholar]
  56. Porter D. C., Ansardi D. C., Wang J., McPherson S., Moldoveanu Z., Morrow C. D. 1998; Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase. Virology 243:1–11 [CrossRef]
    [Google Scholar]
  57. Ranganathan S., Singh S., Poh C. L., Chow V. T. 2002; The hand, foot and mouth disease virus capsid: sequence analysis and prediction of antigenic sites from homology modelling. Appl Bioinformatics 1:43–52
    [Google Scholar]
  58. Ren R., Racaniello V. R. 1992; Human poliovirus receptor gene expression and poliovirus tissue tropism in transgenic mice. J Virol 66:296–304
    [Google Scholar]
  59. Sabin A. B. 1965; Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA 194:872–876 [CrossRef]
    [Google Scholar]
  60. Salk J. E., Bazeley P. L., Bennett B. L., Krech U., Lewis L. J., Ward E. N., Youngner J. S. 1954; Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation. Am J Public Health Nations Health 44:994–1009 [CrossRef]
    [Google Scholar]
  61. Sanford J. R., Gray N. K., Beckmann K., Caceres J. F. 2004; A novel role for shuttling SR proteins in mRNA translation. Genes Dev 18:755–768 [CrossRef]
    [Google Scholar]
  62. Shih S. R., Tsai M. C., Tseng S. N., Won K. F., Shia K. S., Li W. T., Chern J. H., Chen G. W., Lee C. C. other authors 2004; Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother 48:3523–3529 [CrossRef]
    [Google Scholar]
  63. Shimizu H., Agoh M., Agoh Y., Yoshida H., Yoshii K., Yoneyama T., Hagiwara A., Miyamura T. 2000; Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol 74:4146–4154 [CrossRef]
    [Google Scholar]
  64. Si X., Luo H., Morgan A., Zhang J., Wong J., Yuan J., Esfandiarei M., Gao G., Cheung C., McManus B. M. 2005; Stress-activated protein kinases are involved in coxsackievirus B3 viral progeny release. J Virol 79:13875–13881 [CrossRef]
    [Google Scholar]
  65. Tan C. S., Cardosa M. J. 2007; High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol 152:1069–1073 [CrossRef]
    [Google Scholar]
  66. Teterina N. L., Gorbalenya A. E., Egger D., Bienz K., Ehrenfeld E. 1997; Poliovirus protein 2C determinants of membrane binding and rearrangements in mammalian cells. J Virol 71:8962–8972
    [Google Scholar]
  67. Tung W. S., Bakar S. A., Sekawi Z., Rosli R. 2007; DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5:6 [CrossRef]
    [Google Scholar]
  68. Vance L. M., Moscufo N., Chow M., Heinz B. A. 1997; Poliovirus 2C region functions during encapsidation of viral RNA. J Virol 71:8759–8765
    [Google Scholar]
  69. Walter B. L., Nguyen J. H., Ehrenfeld E., Semler B. L. 1999; Differential utilization of poly(rC) binding protein 2 in translation directed by picornavirus IRES elements. RNA 5:1570–1585 [CrossRef]
    [Google Scholar]
  70. Wang S. M., Liu C. C., Tseng H. W., Wang J. R., Huang C. C., Chen Y. J., Yang Y. J., Lin S. J., Yeh T. F. 1999; Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis 29:184–190 [CrossRef]
    [Google Scholar]
  71. Wang S. M., Lei H. Y., Huang K. J., Wu J. M., Wang J. R., Yu C. K., Su I. J., Liu C. C. 2003; Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 188:564–570 [CrossRef]
    [Google Scholar]
  72. Wessels E., Duijsings D., Niu T. K., Neumann S., Oorschot V. M., de Lange F., Lanke K. H., Klumperman J., Henke A. other authors 2006; A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev Cell 11:191–201 [CrossRef]
    [Google Scholar]
  73. Wu T. C., Wang Y. F., Lee Y. P., Wang J. R., Liu C. C., Wang S. M., Lei H. Y., Su I. J., Yu C. K. 2007; Immunity to avirulent enterovirus 71 and Coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 81:10310–10315 [CrossRef]
    [Google Scholar]
  74. Yoshikawa T., Iwasaki T., Ida-Hosonuma M., Yoneyama M., Fujita T., Horie H., Miyazawa M., Abe S., Simizu B., Koike S. 2006; Role of the alpha/beta interferon response in the acquisition of susceptibility to poliovirus by kidney cells in culture. J Virol 80:4313–4325 [CrossRef]
    [Google Scholar]
  75. Yu C. K., Chen C. C., Chen C. L., Wang J. R., Liu C. C., Yan J. J., Su I. J. 2000; Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7:523–528 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.2008/002915-0
Loading
/content/journal/jgv/10.1099/vir.0.2008/002915-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error